Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

about

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

P2860

Q52318443-7FB444EF-5F99-4826-BD33-9EA45B8D4CB4

P2860

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

Item

http://www.wikidata.org/entity/Q47726463

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Patterns of initial and intrac ...... cancer treated with erlotinib.

@en

Patterns of initial and intrac ...... cancer treated with erlotinib.

@nl

type

Item

label

Patterns of initial and intrac ...... cancer treated with erlotinib.

@en

Patterns of initial and intrac ...... cancer treated with erlotinib.

@nl

prefLabel

Patterns of initial and intrac ...... cancer treated with erlotinib.

@en

Patterns of initial and intrac ...... cancer treated with erlotinib.

@nl

P1476

Patterns of initial and intrac ...... cancer treated with erlotinib.

@en

P2093

Abraham J Wu

http://www.w3.org/2001/XMLSchema#string

Amanda Foster

http://www.w3.org/2001/XMLSchema#string

Andreas Rimner

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Helena A Yu

http://www.w3.org/2001/XMLSchema#string

Kaitlin M Woo

http://www.w3.org/2001/XMLSchema#string

Suchit H Patel

http://www.w3.org/2001/XMLSchema#string

Zhigang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

P304

109-114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2017.03.010

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28625621

http://www.w3.org/2001/XMLSchema#string

P932

5477661

http://www.w3.org/2001/XMLSchema#string

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

about

P2860

P2860

Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932